Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-β -D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3577-3585

  Karp, Judith E ^a,b   Gojo, Ivana ^a   Pili, Roberto ^b   Gocke, Christopher D ^a   Greer, Jacqueline ^a,b   Guo, Chuanfa ^a   Qian, David ^b   Morris, Lawrence ^c   Tidwell, Michael ^a   Chen, Helen ^d   Zwiebel, James ^d  

^a UNIVERSITY OF MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Blood and Marrow Transplant Group of Georgia   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; ALUMINUM HYDROXIDE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CORTICOSTEROID; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FAMCICLOVIR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOXANTRONE; NORFLOXACIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG DOSE REGIMEN; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MICROVASCULATURE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; TIMED SEQUENTIAL THERAPY; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MICROCIRCULATION; MIDDLE AGED; MITOXANTRONE; RECOMBINANT PROTEINS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 2542547507     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0627     Document Type: Article

References (50)

1. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35.
2. Gitay-Goren H, Sokert S, Vlodasky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992;267: 6093-98.
3. Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 1997; 386:488-93.
4. Ziegler BL, Valtieri M, Porada A, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 1999;285:1553-8.
5. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-21.
6. Dougher M, Terman BI. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999;18:1619-27.
7. Gerber H-P, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-8.
8. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-34.
9. 165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99:2532-40.
10. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10.
11. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997;89:1870-5.
12. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95: 309-15.
13. Gabrilove JL, White K, Rahman Z, Wilson EL. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 1994;83:907-10.
14. Bikfalvi A, Han ZC. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 1994;8:523-9.
15. Bussolino F, Colotta F, Bocchietto E, Guglielmetti A, Mantovani A. Recent developments in the cell biology of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor: activities on endothelial cells. Int J Clin Res 1993;23:8-12.
16. Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemia cell proliferation, survival and resistance to chemotherapy. Blood 2002;99:2179-84.
17. Padro T, Ruiz S, Bieker H, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95: 2637-44.
18. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-21.
19. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil(FU)/leukovorin (LV) with FU/LV alone in patients with metastatic colon cancer. J Clin Oncol 2003;21:60-5.
20. Hurwitz H, Fehrenbacher L, Cartwright T, et al. bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003;22:abstr 3646.
21. Burke PJ, Karp JE, Braine HG, Vaughan WP. Timed sequential therapy of human leukemia based upon the response to leukemic cells to humoral growth factors. Cancer Res 1977;37:2138-46.
22. Karp JE, Burke PJ. Growth response of residual leukemia after initial drug therapy. Cancer Res 1986;46:4205-7.
23. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989;73:24-30.
24. Archimbaud E, Thomas X, LeBlond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial J Clin Oncol 1995;13:11-8.
25. Bolanos-Meade J, Karp JE, Guo C, et al. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids with the sequential administration of cytosine arabinoside, idarubicin and etoposide. Leuk Res 2003;27:313-21.
26. Geller RB, Burke PJ, Karp JE, et alA two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989;74:1499-505.
27. Martino R, Guardia R, Altes A, Sureda A, Brunet S, Sierra J. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II GEMIA protocol. Haematologica 1999;84:226-30.
28. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group Blood 1996;87:4979-89.
29. Woods WG, Alonzo TA, Lange BJ, Jeha S, Estey EH. Acute Myeloid leukemia (AML) in adolescents and young adults (AYAs): A comparison of outcomes between patients treated on childhood or adult protocols. Blood 2001;98:462a.
30. Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986;70:1059-65.
31. Rosenoff SH, Bostick F, Young RC. Recovery of normal hematopoietic tissue and tumor following chemotherapeutic injury from cyclophosphamide (CTX): comparative analysis of biochemical and clinical techniques. Blood 1975;45:465-75.
32. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. Cancer 1978;42:1747-59.
33. Arlin Z, Case DC Jr, Moore J, et al. Cooperative Group Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990;4:177-83.
34. Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996;14:1345-52.
35. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-24.
36. Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002-9.
37. Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddeman W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Cancer 1997;79:59-68.
38. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
39. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A: 2474-84.
40. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myeloysplastic syndromes. Blood 2000;96: 2240-5.
41. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;76:956-64.
42. McIlhenny C, George WD, Doughty JC. A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers. Br J Cancer 2002;86: 1786-9.
43. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20: 1215-21.
44. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65.
45. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22:3201-12.
46. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
47. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med 2002;8(Suppl):S32-7.
48. Lancet JE, Karp JE. Farnestyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:3880-9.
49. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763-67.
50. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase inhibitor, has biologic activitiy in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.